Dr James M Stone BSc MBBS MRCPsych PhD
Clinical Lecturer
MRC Clinical Research Training Fellow
Honorary Consultant in Psychiatry
 | |
| contact this person | |
| tel | 020 7848 0915 |
| address | Institute of Psychiatry |
| location | 6.07 Main Wing |
| departments | Psychological Medicine and Psychiatry |
| also | Neurochemical Imaging and Psychiatry Neuroimaging |
teaching activities
| Role | Course |
|---|---|
| Lecturer | Neuroscience » Masters (MSc) |
| Lecturer | Mental Health Services Research » Masters (MSc) |
| Lecturer | Psychiatric Research » Masters (MSc) |
| Lecturer | Maudsley Training Programme » MRCPsych |
publications
Stone JM, Davis J, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs – an original patient data meta-analysis of the SPET and PET in vivo receptor imaging literature. Schizophrenia Bulletin 2008 [Epub ahead of print]
McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci. 2008 Jan 8 [Epub ahead of print]
Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, Krystal JH, Ell PJ, Pilowsky LS. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy-a [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl). 2008 Jan 5 [Epub ahead of print]
Stone JM: Glutamatergic Dysfunction in Schizophrenia. Advances in Schizophrenia and Clinical Psychiatry 2007, 3(2): 34-39.
Stone JM, Pilowsky LS: Novel targets for drugs in schizophrenia. CNS Neur. Dis. Drug Targets CNS & Neurol Dis Drug Targ 2007, 6(4):265-72.
Stone JM, Morrison PD, Pilowsy LS: Glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. J. Psychopharmacol. 2007 Jul;21(4):440-52.
Stone JM, Arstad E, Erlandsson K, Waterhouse RN, Ell PJ, Pilowsky LS. [(123)I]TPCNE-A novel SPET tracer for the sigma-1 receptor: First human studies and in vivo haloperidol challenge. Synapse. 2006 May 19;60(2):109-117
Stone JM, Erlandsson K, Arstad E, Bressan RA, Squassante L, Teneggi V, Ell PJ, Pilowsky L. Ketamine displacement of [123I]CNS-1261 – a novel NMDA receptor SPET probe. Nuclear Medicine and Biology 2006 33(2): 239-243
James M Stone, Lyn S Pilowsky Antipsychotic drug action: targets for drug discovery with neurochemical imaging Expert Review of Neurotherapeutics, January 2006, Vol. 6, No. 1, Pages 57-64.
Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, Ell PJ. First In Vivo Evidence Of An NMDA Receptor Deficit In Medication-Free Schizophrenic Patients. Molecular Psychiatry 2006 Feb;11(2):118-9
Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ, Pilowsky LS. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261binding to N-methyl-D-aspartate receptors in vivo. Biol Psychiatry. 2005 Jul 1;58(1):41-6.
Stone JM, Bressan RA, Erlandsson K, Ell PJ, Pilowsky LS. Non-uniform blockade of intrastriatal D(2)/D(3) receptors by risperidone and amisulpride. Psychopharmacology (Berl). 2005 Aug;180(4):664-9. Epub 2005 Sep 14.
Stone JM, Pilowsky LS “Schizophrenia and Psychotic Disorder”. Nuclear Medicine in Psychiatry, Ed: A. Otte, K. Audenaert, K. van Heeringen and R.A. Dierckx. Springer 2004 pp301-310.
Stone JM, Pilowsky LS “Monitoring Treatment Effects”. Psychiatric Neuroimaging V. Ng et. al. (Eds.) IOS Press 2003 pp156-160
Stone JM, Ohlsen R, Taylor D, Pilowsky LS “A Naturalistic Study of the Antipsychotic Medication Review Service at the Maudsley Hospital”. Psychiatric Bulletin 2002 26 291-4
Stone JM, Szmukler G “An Audit of Risk Assessment in an Emergency Setting”. Psychiatric Bulletin 2002 26 88-90
A. Hartley, J.M. Stone, C. Heron, J.M. Cooper and A.H.V Schapira. “Complex I Inhibitors Induce Dose-Dependent Apoptosis in PC12 Cells: Relevance to Parkinson’s Disease”. Journal of Neurochemistry (1994) 63 1987-1990
last updated: Friday, March 07, 2008